Alzheimer's Treatments 2025: Here's Every FDA-Approved …
Jul 15, 2024 · Here’s what patients, caregivers and clinicians need to know about every FDA-approved Alzheimer's treatment — and where each option fits in.
FDA approves treatment for adults with Alzheimer’s disease
Jul 2, 2024 · The Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease.
FDA Approves Leqembi Subcutaneous Maintenance Dosing
Aug 29, 2025 · With this approval, Leqembi IQLIK is the first monoclonal antibody that clears amyloid beta for the treatment of early Alzheimer’s disease that is approved for subcutaneous …
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) …
Aug 29, 2025 · LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless …
Alzheimer’s Therapy Is Coming to the Home With FDA Approval …
Sep 2, 2025 · The Eisai- and Biogen-partnered Alzheimer’s disease drug Leqembi has been available to date as an intravenous infusion that takes about an hour.
Fact Check: What major Alzheimer’s treatments have FDA approved …
Oct 30, 2025 · The approval of lecanemab and donanemab marks a clear regulatory recognition that targeting beta‑amyloid can produce measurable slowing of clinical decline in early …
FDA approves at-home injection for Alzheimer's treatment
The US Food and Drug Administration (FDA) has approved a new version of an Alzheimer’s disease drug that can be given as a quick at-home weekly injection, offering patients a far …
Biogen & Eisai Win FDA Approval for New Form of Alzheimer’s …
Sep 11, 2025 · Biogen and Eisai have won FDA approval for a new form of their anti-amyloid Alzheimer drug Leqembi: an autoinjector that can be used to administer the drug in the home …
FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease
Sep 2, 2025 · FDA approval was supported by phase 3 Clarity AD extension trial data, showing that switching to the weekly Leqembi Iqlik autoinjector after 18 months of IV dosing maintains …
Lecanemab SC Formulation Approved for Maintenance Dosing in …
Sep 2, 2025 · FDA approves Leqembi® Iqlik™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease. News release. Eisai and …